|
ATE513563T1
(de)
|
2000-10-09 |
2011-07-15 |
Isis Innovation |
Therapeutische und toleranz-induzierende antikörper
|
|
US8293685B2
(en)
|
2007-07-26 |
2012-10-23 |
The Regents Of The University Of California |
Methods for enhancing bacterial cell display of proteins and peptides
|
|
WO2009021754A2
(en)
|
2007-08-15 |
2009-02-19 |
Bayer Schering Pharma Aktiengesellschaft |
Monospecific and multispecific antibodies and method of use
|
|
CA2697032C
(en)
*
|
2007-08-22 |
2021-09-14 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
US8895702B2
(en)
|
2008-12-08 |
2014-11-25 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
|
|
US20100189651A1
(en)
*
|
2009-01-12 |
2010-07-29 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
|
JP5861223B2
(ja)
|
2009-02-23 |
2016-02-16 |
サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. |
プロタンパク質およびその使用方法
|
|
WO2010111625A1
(en)
*
|
2009-03-27 |
2010-09-30 |
Zymogenetics, Inc. |
Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
|
|
US9193791B2
(en)
*
|
2010-08-03 |
2015-11-24 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects
|
|
HRP20150664T1
(hr)
*
|
2010-12-03 |
2015-07-31 |
Adamed Sp. Z O.O. |
Antikancerogeni fuzijski protein
|
|
BR112013022557A2
(pt)
*
|
2011-03-04 |
2017-08-01 |
Shire Human Genetic Therapies |
ligantes de peptídeo composições de polipeptídeo e métodos para uso dos mesmos
|
|
US8580922B2
(en)
|
2011-03-04 |
2013-11-12 |
Shire Human Genetic Therapies, Inc. |
Peptide linkers for polypeptide compositions and methods for using same
|
|
JP6130307B2
(ja)
|
2011-03-17 |
2017-05-17 |
ザ ユニバーシティ オブ バーミンガム |
再指向性免疫療法
|
|
PL394618A1
(pl)
*
|
2011-04-19 |
2012-10-22 |
Adamed Spólka Z Ograniczona Odpowiedzialnoscia |
Przeciwnowotworowe bialko fuzyjne
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
CN104540518A
(zh)
|
2012-04-27 |
2015-04-22 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
US8822423B2
(en)
*
|
2012-05-17 |
2014-09-02 |
Janssen Biotech, Inc. |
Affinity peptides toward infliximab
|
|
MX2014016038A
(es)
|
2012-06-22 |
2015-08-14 |
Cytomx Therapeutics Inc |
Anticuerpos de reaccion cruzada anti - jagged 1 / jagged 2, anticuerpos anti - jagged activables y metodos para uso de los mismos.
|
|
WO2013192546A1
(en)
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and mehtods of using the same
|
|
US9309510B2
(en)
|
2012-08-10 |
2016-04-12 |
Cytomx Therapeutics, Inc. |
Protease-resistant systems for polypeptide display and methods of making and using thereof
|
|
US9376489B2
(en)
|
2012-09-07 |
2016-06-28 |
Novartis Ag |
IL-18 binding molecules
|
|
US9487590B2
(en)
|
2012-09-25 |
2016-11-08 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
|
|
CA2896282C
(en)
|
2013-01-04 |
2021-07-20 |
Cytomx Therapeutics, Inc. |
Compositions and methods for detecting protease activity in biological systems
|
|
CA2906095A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Bayer Healthcare Llc |
Pro-drug antibodies against tissue factor pathway inhibitor
|
|
WO2014193973A2
(en)
*
|
2013-05-28 |
2014-12-04 |
Dcb-Usa Llc |
Antibody locker for the inactivation of protein drug
|
|
US9517276B2
(en)
*
|
2013-06-04 |
2016-12-13 |
Cytomx Therapeutics, Inc. |
Compositions and methods for conjugating activatable antibodies
|
|
US20170319709A1
(en)
|
2013-07-05 |
2017-11-09 |
Formation Biologics Inc. |
Egfr antibody conjugates
|
|
CN105722859B
(zh)
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
|
CA2925106C
(en)
*
|
2013-09-25 |
2023-11-14 |
Cytomx Therapeutics, Inc. |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
US9737623B2
(en)
|
2013-12-11 |
2017-08-22 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
UA129760C2
(uk)
|
2013-12-17 |
2025-07-30 |
Дженентек, Інк. |
Анти-cd3 антитіло та спосіб його застосування
|
|
CN105899539B
(zh)
|
2014-01-10 |
2021-11-09 |
博笛生物科技有限公司 |
用于免疫疗法的化合物和组合物
|
|
IL270562B
(en)
|
2014-01-31 |
2022-08-01 |
Cytomx Therapeutics Inc |
Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
|
|
EP3166976B2
(en)
|
2014-07-09 |
2026-04-08 |
Birdie Biopharmaceuticals Inc. |
Anti-pd-l1 combinations for treating tumors
|
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
JP7020909B2
(ja)
|
2014-07-25 |
2022-02-16 |
シトムクス セラピューティクス，インコーポレイティド |
抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
|
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
MY189836A
(en)
|
2014-11-21 |
2022-03-11 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
|
CN107207594B
(zh)
|
2014-12-23 |
2019-05-07 |
百时美施贵宝公司 |
针对tigit的抗体
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
US10441649B2
(en)
|
2015-02-02 |
2019-10-15 |
The University Of Birmingham |
Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
|
|
CN108112254B
(zh)
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
CN107849133B
(zh)
|
2015-05-04 |
2022-08-23 |
西托姆克斯治疗公司 |
抗cd166抗体、可活化抗cd166抗体及其使用方法
|
|
CA2984892A1
(en)
|
2015-05-04 |
2016-11-10 |
Cytomx Therapeutics, Inc. |
Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
|
|
BR112017023862A2
(pt)
|
2015-05-04 |
2018-07-17 |
Cytomx Therapeutics Inc |
anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
|
|
WO2016182064A1
(ja)
|
2015-05-13 |
2016-11-17 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
EA201792573A1
(ru)
|
2015-05-21 |
2018-04-30 |
Харпун Терапьютикс, Инк. |
Триспецифические связанные белки и способы их применения
|
|
TN2019000101A1
(en)
|
2015-05-29 |
2020-07-15 |
Bristol Myers Squibb Co |
Antibodies against ox40 and uses thereof.
|
|
MA44594B1
(fr)
|
2015-05-29 |
2020-09-30 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
|
|
EP3302467A4
(en)
|
2015-05-31 |
2019-01-02 |
Curegenix Corporation |
Combination compositions for immunotherapy
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
WO2016210447A1
(en)
|
2015-06-26 |
2016-12-29 |
University Of Southern California |
Masking chimeric antigen receptor t cells for tumor-specific activation
|
|
AU2016285920A1
(en)
|
2015-06-29 |
2018-02-01 |
Bristol-Myers Squibb Company |
Antibodies to CD40 with enhanced agonist activity
|
|
CN114591433A
(zh)
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
US11466093B2
(en)
|
2015-07-27 |
2022-10-11 |
The General Hospital Corporation |
Antibody derivatives with conditionally enabled effector function
|
|
WO2017027422A1
(en)
|
2015-08-07 |
2017-02-16 |
Alexo Therapeutics Inc. |
Constructs having a sirp-alpha domain or variant thereof
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
JP7115982B2
(ja)
|
2015-10-30 |
2022-08-09 |
アレタ・バイオセラピューティクス・インコーポレイテッド |
癌の治療のための組成物及び方法
|
|
KR20180083868A
(ko)
|
2015-10-30 |
2018-07-23 |
알레타 바이오쎄라퓨틱스, 인크. |
종양 형질도입용 조성물 및 방법
|
|
ES2873846T5
(en)
|
2015-11-19 |
2025-06-23 |
Revitope Ltd |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
|
|
WO2017106630A1
(en)
|
2015-12-18 |
2017-06-22 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
|
KR20230038311A
(ko)
|
2016-03-04 |
2023-03-17 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd73 항체와의 조합 요법
|
|
CN116987189A
(zh)
|
2016-05-20 |
2023-11-03 |
哈普恩治疗公司 |
单链可变片段cd3结合蛋白质
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
JP7101621B2
(ja)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス，インク． |
単一ドメイン血清アルブミン結合タンパク質
|
|
WO2017211278A1
(en)
|
2016-06-06 |
2017-12-14 |
Asclepiumm Taiwan Co., Ltd |
Antibody fusion proteins for drug delivery
|
|
JP7185530B2
(ja)
|
2016-06-13 |
2022-12-07 |
トルク セラピューティクス， インコーポレイテッド |
免疫細胞機能を促進するための方法および組成物
|
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
MX2019004775A
(es)
*
|
2016-11-03 |
2019-08-05 |
Squibb Bristol Myers Co |
Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
EP3544629A4
(en)
|
2016-11-23 |
2020-06-17 |
Harpoon Therapeutics, Inc. |
PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
|
|
CN110198955A
(zh)
|
2016-11-23 |
2019-09-03 |
哈普恩治疗公司 |
前列腺特异性膜抗原结合蛋白质
|
|
TWI797097B
(zh)
|
2016-11-28 |
2023-04-01 |
日商中外製藥股份有限公司 |
包含抗原結合域與運送部分的多胜肽
|
|
WO2018097308A1
(ja)
|
2016-11-28 |
2018-05-31 |
中外製薬株式会社 |
リガンド結合活性が調整可能なリガンド結合分子
|
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
|
WO2018106862A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
EA201991353A1
(ru)
|
2016-12-09 |
2019-11-29 |
|
Двухвалентные антитела, маскированные спирализованными спиралями
|
|
MA47613A
(fr)
*
|
2017-02-22 |
2020-01-01 |
Aleta Biotherapeutics Inc |
Compositions et procédés de traitement du cancer
|
|
JP7556687B2
(ja)
|
2017-02-24 |
2024-09-26 |
中外製薬株式会社 |
薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
|
|
WO2018160671A1
(en)
*
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Targeted checkpoint inhibitors and methods of use
|
|
EP3589662A4
(en)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
|
|
WO2018165619A1
(en)
|
2017-03-09 |
2018-09-13 |
Cytomx Therapeutics, Inc. |
Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
AU2018250641B2
(en)
|
2017-04-11 |
2025-03-13 |
Inhibrx Biosciences, Inc. |
Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
|
|
US12460208B2
(en)
|
2017-04-18 |
2025-11-04 |
Parr Biotechnology Co., Ltd. |
Immunomodulatory polynucleotides and uses thereof
|
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
|
WO2018209304A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
AU2018265856B2
(en)
|
2017-05-12 |
2023-04-27 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
US11643463B2
(en)
|
2017-05-19 |
2023-05-09 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
|
|
WO2018219301A1
(zh)
*
|
2017-05-31 |
2018-12-06 |
四川大学华西医院 |
一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
|
|
JP2020522486A
(ja)
|
2017-06-01 |
2020-07-30 |
サイトメックス セラピューティクス インコーポレイテッド |
活性化可能抗ｐｄｌ１抗体、およびその使用方法
|
|
CN111050803A
(zh)
*
|
2017-06-20 |
2020-04-21 |
德克萨斯大学系统董事会 |
用于治疗癌症的干扰素前药
|
|
JP7187048B2
(ja)
|
2017-06-30 |
2022-12-12 |
マサチューセッツ インスティテュート オブ テクノロジー |
分枝多官能性マクロモノマーおよび関連ポリマーならびにそれらの使用
|
|
MX2020000435A
(es)
|
2017-07-14 |
2020-08-17 |
Cytomx Therapeutics Inc |
Anticuerpos anti-cd166 y usos de estos.
|
|
JP2020530554A
(ja)
|
2017-07-20 |
2020-10-22 |
シートムエックス セラピューティクス，インコーポレイテッド |
活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
|
|
CN111278461A
(zh)
|
2017-08-16 |
2020-06-12 |
百时美施贵宝公司 |
可前药化抗体、其前药以及使用和制备方法
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
MX2020002198A
(es)
|
2017-08-30 |
2020-07-20 |
Cytomx Therapeutics Inc |
Anticuerpos anti-cd166 activables y métodos de uso de los mismos.
|
|
HRP20241268T1
(hr)
|
2017-10-13 |
2024-12-06 |
Harpoon Therapeutics, Inc. |
Trispecifični proteini i postupci primjene
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
RU2771292C2
(ru)
|
2017-10-14 |
2022-04-29 |
Эббви Инк. |
Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения
|
|
CA3287794A1
(en)
|
2017-10-14 |
2025-10-27 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
CA3081539A1
(en)
*
|
2017-11-08 |
2019-05-16 |
Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. |
Conjugates of biomolecule and use thereof
|
|
CN111836828B
(zh)
|
2017-11-28 |
2024-12-20 |
中外制药株式会社 |
包括抗原结合结构域和运送部分的多肽
|
|
CN111630062A
(zh)
|
2017-11-28 |
2020-09-04 |
中外制药株式会社 |
具有可调节的配体结合活性的配体结合分子
|
|
KR20200091901A
(ko)
|
2017-12-01 |
2020-07-31 |
시애틀 지네틱스, 인크. |
암을 치료하기 위한 cd47 항체 및 이의 용도
|
|
CN111788227B
(zh)
|
2017-12-27 |
2025-02-25 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
WO2019160007A1
(ja)
|
2018-02-14 |
2019-08-22 |
中外製薬株式会社 |
抗原結合分子および組合せ
|
|
WO2019173832A2
(en)
*
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
WO2019173771A1
(en)
|
2018-03-09 |
2019-09-12 |
Cytomx Therapeutics, Inc. |
Activatable cd147 antibodies and methods of making and use thereof
|
|
JP2021518603A
(ja)
|
2018-03-20 |
2021-08-02 |
シートムエックス セラピューティクス，インコーポレイテッド |
哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
|
|
BR112020019083A2
(pt)
|
2018-03-21 |
2020-12-29 |
Five Prime Therapeutics, Inc. |
Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
|
|
BR112020020604A2
(pt)
|
2018-04-11 |
2021-01-12 |
Inhibrx, Inc. |
Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
|
|
TW202014436A
(zh)
|
2018-05-02 |
2020-04-16 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
抗體、可活化之抗體、雙特異性抗體、及雙特異性可活化之抗體及使用彼之方法
|
|
EP3787691A1
(en)
|
2018-05-04 |
2021-03-10 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
KR20210020903A
(ko)
*
|
2018-05-14 |
2021-02-24 |
하푼 테라퓨틱스, 인크. |
면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
|
|
CA3100005A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
EP3794044A4
(en)
*
|
2018-05-14 |
2022-02-16 |
Harpoon Therapeutics, Inc. |
DOUBLE BINDING UNIT
|
|
WO2019230868A1
(ja)
|
2018-05-30 |
2019-12-05 |
中外製薬株式会社 |
単ドメイン抗体含有リガンド結合分子
|
|
US12077577B2
(en)
|
2018-05-30 |
2024-09-03 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide comprising aggrecan binding domain and carrying moiety
|
|
EP3810624A4
(en)
|
2018-06-22 |
2022-07-06 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
BR112021000303A2
(pt)
|
2018-07-11 |
2021-04-13 |
Five Prime Therapeutics, Inc. |
Anticorpos que se ligam a vista em ph ácido
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
US12459980B2
(en)
|
2018-07-25 |
2025-11-04 |
AskGene Pharma, Inc. |
IL-21 prodrugs and methods of use thereof
|
|
MA53333A
(fr)
*
|
2018-07-31 |
2021-11-03 |
Amgen Inc |
Formulations pharmaceutiques d'anticorps masqués
|
|
MX2021000827A
(es)
|
2018-08-03 |
2021-03-25 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
|
|
EP3837266A1
(en)
|
2018-08-17 |
2021-06-23 |
Massachusetts Institute of Technology |
Degradable polymers of a cyclic silyl ether and uses thereof
|
|
EP3849611A4
(en)
*
|
2018-09-11 |
2022-06-15 |
Georgia Tech Research Corporation |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY PROFILING
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
SG11202103022WA
(en)
|
2018-09-25 |
2021-04-29 |
Harpoon Therapeutics Inc |
Dll3 binding proteins and methods of use
|
|
BR112021005472A2
(pt)
|
2018-09-28 |
2021-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
molécula de ligação ao antígeno compreendendo uma região variável do anticorpo alterada
|
|
CA3115082A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
EP3864045A2
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
WO2020076992A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
WO2020077257A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
TWI897855B
(zh)
|
2018-10-26 |
2025-09-21 |
美商免疫遺傳股份有限公司 |
Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
|
|
MX2021005116A
(es)
|
2018-11-02 |
2021-07-15 |
Cytomx Therapeutics Inc |
Anticuerpos activables anti-cd166 y metodos de uso de estos.
|
|
US11274150B2
(en)
|
2018-11-16 |
2022-03-15 |
Bristol-Myers Squibb Company |
Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
|
|
MY205459A
(en)
|
2018-12-06 |
2024-10-22 |
Cytomx Therapeutics Inc |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
|
BR112021012536A2
(pt)
|
2018-12-26 |
2021-09-14 |
City Of Hope |
Proteínas de ligação anti-ctla4 mascaradas ativáveis
|
|
WO2020176672A1
(en)
|
2019-02-26 |
2020-09-03 |
Cytomx Therapeutics, Inc. |
Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
|
|
CN113544509A
(zh)
*
|
2019-03-08 |
2021-10-22 |
牛津遗传学有限公司 |
选择抗体的方法
|
|
EP3937979A4
(en)
|
2019-03-13 |
2023-03-08 |
Merck Sharp & Dohme LLC |
COMBINATIONAL ANTI-CANCER THERAPIES WITH CTLA-4 AND PD-1 BLOCKING AGENTS
|
|
US11833214B2
(en)
|
2019-03-21 |
2023-12-05 |
Immunogen, Inc. |
Methods of preparing cell-binding agent-drug conjugates
|
|
US11851487B2
(en)
*
|
2019-04-01 |
2023-12-26 |
Rensselaer Polytechnic Institute |
Methods and systems for detecting peptide aggregates
|
|
US12582726B1
(en)
|
2019-04-05 |
2026-03-24 |
Earli Inc. |
Synthetic cancer-specific promoters
|
|
EP4600650A3
(en)
|
2019-04-05 |
2025-11-26 |
Earli Inc. |
Improved methods and compositions for synthetic biomarkers
|
|
JP7720785B2
(ja)
|
2019-04-18 |
2025-08-08 |
ブリストル－マイヤーズ スクイブ カンパニー |
低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
|
|
JP7561141B2
(ja)
|
2019-04-26 |
2024-10-03 |
イミュノジェン・インコーポレーテッド |
カンプトテシン誘導体
|
|
US12516128B2
(en)
|
2019-05-14 |
2026-01-06 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
KR20220023988A
(ko)
|
2019-05-14 |
2022-03-03 |
웨어울프 세라퓨틱스, 인크. |
분리 모이어티 및 이의 사용 방법
|
|
AU2020278465B2
(en)
|
2019-05-20 |
2026-04-23 |
Dana-Farber Cancer Institute, Inc. |
Boronic ester prodrugs and uses thereof
|
|
BR112021024003A2
(pt)
|
2019-05-31 |
2022-04-19 |
Alx Oncology Inc |
Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
|
|
US20220306727A1
(en)
|
2019-06-05 |
2022-09-29 |
Seagen Inc. |
Methods of Purifying Masked Antibodies
|
|
US20220233709A1
(en)
|
2019-06-05 |
2022-07-28 |
Seagen Inc. |
Masked Antibody Formulations
|
|
JPWO2020246563A1
(https=)
|
2019-06-05 |
2020-12-10 |
|
|
|
US20220251206A1
(en)
|
2019-06-11 |
2022-08-11 |
Bristol-Myers Squibb Company |
Anti-ctla4 antibody prodruggable (probody) at a cdr position
|
|
KR20220020879A
(ko)
|
2019-06-12 |
2022-02-21 |
에스크진 파마, 아이엔씨. |
새로운 il-15 프로드럭 및 이를 사용하는 방법
|
|
EP3983439A1
(en)
|
2019-06-13 |
2022-04-20 |
CytomX Therapeutics, Inc. |
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
|
|
EP3983440A1
(en)
|
2019-06-13 |
2022-04-20 |
CytomX Therapeutics, Inc. |
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer
|
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
|
EP4382129A3
(en)
|
2019-06-17 |
2024-07-03 |
Tagworks Pharmaceuticals B.V. |
Compounds for fast and efficient click release
|
|
US20220289822A1
(en)
*
|
2019-08-21 |
2022-09-15 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
CN112480263A
(zh)
*
|
2019-09-12 |
2021-03-12 |
普米斯生物技术(苏州)有限公司 |
一种双特异t细胞激活器活化t细胞的设计及其应用
|
|
EP4031575A1
(en)
|
2019-09-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
EP4034171A1
(en)
|
2019-09-23 |
2022-08-03 |
Cytomx Therapeutics Inc. |
Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
AU2020394204A1
(en)
|
2019-11-27 |
2022-06-02 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
WO2021141662A1
(en)
|
2020-01-10 |
2021-07-15 |
Massachusetts Institute Of Technology |
Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof
|
|
WO2021142471A1
(en)
|
2020-01-11 |
2021-07-15 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
|
CN115380047A
(zh)
|
2020-01-29 |
2022-11-22 |
印希比股份有限公司 |
Cd28单结构域抗体及其多价和多特异性构建体
|
|
CN115175930A
(zh)
|
2020-02-05 |
2022-10-11 |
中外制药株式会社 |
用于产生和/或富集重组抗原结合分子的方法
|
|
CA3170833A1
(en)
|
2020-02-21 |
2021-08-26 |
Harpoon Therapeutics, Inc. |
Flt3 binding proteins and methods of use
|
|
WO2021183428A1
(en)
|
2020-03-09 |
2021-09-16 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
TWI909146B
(zh)
|
2020-03-31 |
2025-12-21 |
日商中外製藥股份有限公司 |
Dll3靶向之多特異性抗原結合分子及其用途
|
|
BR112022019841A2
(pt)
|
2020-04-09 |
2022-12-06 |
Cytomx Therapeutics Inc |
Composições contendo anticorpos ativáveis
|
|
AU2021254283B2
(en)
|
2020-04-10 |
2025-12-11 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
IL300623A
(en)
|
2020-08-21 |
2023-04-01 |
Genzyme Corp |
Anti-FGFR3 antibodies and methods of use
|
|
AU2021374594B2
(en)
|
2020-11-04 |
2026-03-05 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
KR20230100732A
(ko)
|
2020-11-04 |
2023-07-05 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이성 항체의 피하 투여
|
|
CA3196539A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
US20220153869A1
(en)
*
|
2020-11-16 |
2022-05-19 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof
|
|
EP4247850A1
(en)
|
2020-11-20 |
2023-09-27 |
Simcere Innovation, Inc. |
Armed dual car-t compositions and methods for cancer immunotherapy
|
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
|
WO2022170619A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|
|
JP2024509890A
(ja)
*
|
2021-03-09 |
2024-03-05 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
プロテアーゼ切断可能なプロドラッグ
|
|
JP2024511387A
(ja)
|
2021-03-16 |
2024-03-13 |
シートムエックス セラピューティクス，インコーポレイテッド |
マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
JP2024520902A
(ja)
|
2021-05-13 |
2024-05-27 |
エーエルエックス オンコロジー インコーポレイテッド |
がんを治療するための併用療法
|
|
US12291575B2
(en)
|
2021-05-14 |
2025-05-06 |
Genentech, Inc. |
Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
EP4370211A1
(en)
|
2021-07-14 |
2024-05-22 |
Seagen Inc. |
Antibody masking domains
|
|
JP2024527582A
(ja)
|
2021-07-19 |
2024-07-25 |
中外製薬株式会社 |
融合ポリペプチドを用いるプロテアーゼ媒介性の標的特異的サイトカイン送達
|
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
|
WO2023064791A1
(en)
|
2021-10-13 |
2023-04-20 |
Cytomx Therapeutics, Inc. |
Trimeric activatable cytokine constructs and related compositions and methods
|
|
US20250000892A1
(en)
*
|
2021-10-14 |
2025-01-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Programmable delivery platforms for rna structures
|
|
WO2023064955A1
(en)
|
2021-10-15 |
2023-04-20 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
|
|
JP2024539650A
(ja)
|
2021-10-15 |
2024-10-29 |
シートムエックス セラピューティクス，インコーポレイテッド |
活性化可能なポリペプチド複合体
|
|
AU2022367525A1
(en)
|
2021-10-15 |
2024-05-02 |
Amgen Inc. |
Activatable polypeptide complex
|
|
IL312728A
(en)
|
2021-11-30 |
2024-07-01 |
Daiichi Sankyo Co Ltd |
Protease-cleavable masked antibodies
|
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
US20250170255A1
(en)
|
2022-02-09 |
2025-05-29 |
Daiichi Sankyo Company, Limited |
Environmentally-responsive masked antibody and use thereof
|
|
US20250333487A1
(en)
|
2022-03-25 |
2025-10-30 |
Cytomx Therapeutics, Inc. |
Activatable dual-anchored masked molecules and methods of use thereof
|
|
JP2025511187A
(ja)
|
2022-04-01 |
2025-04-15 |
サイトムエックス セラピューティクス，インク． |
Ｃｄ３結合タンパク質及びその使用方法
|
|
WO2023192973A1
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Activatable multispecific molecules and methods of use thereof
|
|
CA3251998A1
(en)
|
2022-05-16 |
2023-11-23 |
Byondis B.V. |
Novel masked antibodies
|
|
JP2025524628A
(ja)
|
2022-07-12 |
2025-07-30 |
シートムエックス セラピューティクス，インコーポレイテッド |
Ｅｐｃａｍイムノコンジュゲート及びその使用
|
|
AR130079A1
(es)
|
2022-08-01 |
2024-10-30 |
Cytomx Therapeutics Inc |
Restos escindibles por proteasas, y métodos de uso de los mismos
|
|
US20260042849A1
(en)
|
2022-08-01 |
2026-02-12 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
|
TW202424183A
(zh)
|
2022-08-01 |
2024-06-16 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
蛋白酶可切割受質及其使用方法
|
|
JP2025525868A
(ja)
|
2022-08-01 |
2025-08-07 |
サイトムエックス セラピューティクス，インク． |
プロテアーゼ切断性部分及びその使用方法
|
|
JP2025525879A
(ja)
|
2022-08-01 |
2025-08-07 |
サイトムエックス セラピューティクス，インク． |
プロテアーゼ切断性基質及びその使用方法
|
|
WO2024031036A2
(en)
*
|
2022-08-05 |
2024-02-08 |
Staidson Biopharma Inc. |
Il-15 prodrug and uses thereof
|
|
WO2024150172A1
(en)
*
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Cleavable peptides and methods of use thereof
|
|
WO2024150175A1
(en)
*
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated proteins and methods of use
|
|
WO2024216170A2
(en)
|
2023-04-12 |
2024-10-17 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
WO2024216146A1
(en)
|
2023-04-12 |
2024-10-17 |
Cytomx Therapeutics, Inc. |
Masking polypeptides, activatable cytokine constructs, and related compositions and methods
|
|
WO2024212151A1
(en)
*
|
2023-04-13 |
2024-10-17 |
Adagene Pte. Ltd. |
Masked antibodies, libraries and methods of use
|
|
AU2024296516A1
(en)
|
2023-07-13 |
2026-01-22 |
Iovance Biotherapeutics, Inc. |
Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
|
|
WO2025038668A1
(en)
|
2023-08-14 |
2025-02-20 |
Voro Therapeutics, Inc. |
Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
|
|
CN117534732B
(zh)
*
|
2023-11-03 |
2024-10-22 |
湖南中晟全肽生物科技股份有限公司 |
一种抑制il-12与其受体结合的多肽及其应用
|
|
TW202540188A
(zh)
|
2023-12-01 |
2025-10-16 |
比利時商艾伯霖克斯公司 |
精準活化的多肽
|
|
WO2025235515A1
(en)
|
2024-05-07 |
2025-11-13 |
Cytomx Therapeutics, Inc. |
Activatable polypeptide complex formulations
|
|
WO2025240659A2
(en)
|
2024-05-14 |
2025-11-20 |
Cytomx Therapeutics, Inc. |
Activatable constructs, compositions and methods
|
|
WO2026006784A1
(en)
|
2024-06-28 |
2026-01-02 |
Iovance Biotherapeutics, Inc. |
Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
|
|
WO2026020161A1
(en)
|
2024-07-19 |
2026-01-22 |
Cytomx Therapeutics, Inc. |
Activatable il-12 constructs and related compositions and methods
|
|
WO2026024841A1
(en)
|
2024-07-24 |
2026-01-29 |
Astellas Us Llc |
Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
|
|
WO2026035650A2
(en)
|
2024-08-05 |
2026-02-12 |
Cytomx Therapeutics, Inc. |
Cleavable polypeptides and methods of use thereof
|